Living in areas with lower COI levels was associated with more severe disease presentation and poorer disease control among patients with cSLE.

The proportion of children achieving a clinically meaningful ... patients were consistent with those in adults with systemic lupus erythematosus (SLE). Benlysta has been approved for use in ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus ...

Incurable Autoimmune Disease Systemic Lupus Erythematosus (SLE): New Genetic Findings Open Up Perspectives for Future Therapeutic Approaches Jan. 14, 2024 — Systemic lupus erythematosus (SLE ...

Children born to anti-Ro antibody-positive mothers do not exhibit a greater prevalence of allergic, neurodevelopmental, or autoimmune conditions.

In a new study, researchers evaluated the potential relationship between disordered eating attitudes and nutritional status ...

Biomarkers that reliably identify or even predict disease manifestations in systemic lupus erythematosus (SLE) are needed. In a recent issue of the Clinical Journal of the American Society of ...

Based on the information that is currently available, decision makers have agreed that the subject technology would be appropriate for commissioning under NHSE Specialised Commissioning for Children ...

Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

For treating systemic lupus erythematosus (SLE), the usual recommended ... Benlysta can be used in adults and children ages 5 years and older. Both Saphnelo and Benlysta are biologic drugs.

The Saint Louis University Division of Rheumatology specializes in the care of both adults and children with rheumatic diseases with an emphasis on rheumatoid arthritis (RA), juvenile idiopathic ...